In the 1974 movie Young Frankenstein, the late great Gene Wilder, portraying the eccentric Dr Frederick Frankenstein, proclaims to his young medical student, ''Hearts and kidneys are tinkertoys! I am talking about the central nervous system!'' 1 This indeed is the prevailing philosophy for poststroke cerebral edema management in the neurological intensive care unit (NICU). Large strokes, especially those involving the middle cerebral artery territory, have a high incidence of clinical deterioration due to cerebral edema-which can occur in about two-thirds of cases and be ''malignant'' or fatal in about half. 2 So what is the antidote for cerebral edema? Beyond surgical craniectomy, which is more of a reactive than a proactive measure, the most common medical therapy is either mannitol or hypertonic saline (HTS), both of which have been associated with cardiotoxic and nephrotoxic side effects. Regardless, if these medications are able to mitigate strokeinduced cerebral edema and thereby save patients' brains from swelling and dying, then why would anyone fret about theoretical damage to hearts and kidneys???
The answer is, unfortunately, because many practitioners are not uniformly convinced of the benefits of these edemamitigating medications. Even guidelines are mixed. Currently, the usefulness of HTS for the treatment of deteriorating patients with malignant brain edema after large cerebral infarction is ''incompletely established'' and has been given Class IIb, Level of Evidence C in the 2013 Stroke guidelines. 3 A newer recommendation for HTS by the Neurocritical Care Society is somewhat more robust: strong recommendation with moderate level of evidence. 4 Data with HTS do exist: a retrospective cohort, using HTS for supratentorial lesions, was associated with a drop in intracranial pressure (ICP) and reversal of clinical transtentorial herniation. 5 In yet another study, the absolute and relative volumes of perihemorrhagic stroke edema were significantly smaller for HTS-treated patients, who also experienced less ICP crises and decreased inhospital mortality (11.5% for HTS vs 25% in the control group). 6 In this study, rates of side effects supposedly associated with HTS, such as cardiac arrhythmia, congestive heart failure, and acute kidney injury (AKI), were actually statistically similar in both groups. Nevertheless, in this month's The Neurohospitalist, Erdman and colleagues report the results of their 2-center, retrospective study of patients with ''cerebral edema that necessitated continuous HTS infusions'' between 2012 and 2014. 7 Their aim, they stated, was to ''identify predictors of AKI'' as defined by Acute Kidney Injury Network (AKIN) classification and provide clinicians with ''factors that should be considered when initiating HTS infusions.'' They hypothesize that CKD, severe hypernatremia, use of the antibiotic piperacillin/tazobactam (Zosyn), male sex, and African American race are possible predictors of AKI.
They concluded, ''16% of patients receiving HTS developed AKI and the median time of initiation of HTS infusion to occurrence of AKI'' was about 79 hours. In a dynamic NICU, it is very likely that over 3 days, a panoply of events, complications, and decisions (other than just HTS use) were involved in the management of ill patients with large strokes. Nephrotoxic polypharmacy, vital sign flux with acute hypotension or hypertension, intracranial and extracranial fluid shifts, acuteon-chronic exacerbations of intrinsic baseline cardiac and/ or renal disease, and so many other factors could also provoke AKI. Authors provide a partial list of medications patients received, such as the antibiotic piperacillin/tazobactam, but did not name any sedatives, paralytics, or narcotics that they likely utilized, given their mechanical ventilation rate of 57%. Also, Zosyn contains a high sodium concentration itself (64 mg [2.79 mEq] of sodium per gram of piperacillin) meaning that at the typical doses, patients receive an extra salt load (between 768 and 1024 mg/d [33.5-44.6 mEq of sodium])-so naturally HTS and Zosyn could produce an iatrogenic AKI. 8 Just because some patients who were given HTS developed AKI does not confirm HTS directly caused AKI. Correlation is not causation. Explicitly, the AKIN criteria call for volume status optimization and exclusion of urinary tract obstructions. 9 These authors did not mention these AKIN prerequisites. Further, it is unclear when AKI occurred relative to hospital admission, as we are only provided AKI onset relative to HTS administration. Authors state 28 patients had stage 1 AKI, 13 had stage 2, and 13 had stage 3 and that 3 required HD-each AKI group was not separately compared against a non-AKI group-in this study, all 3 AKI stages were lumped together and then compared. A transient increase in serum creatinine is a reflection of a change in renal physiologic function-Creatinine rises temporarily, then returns to baseline when drug is discontinued-similar to angiotensinconverting enzyme inhibitors. 10 Were other parameters of renal function measured? Were nephrologists involved in the care of these patients with CKD on admission to fully diagnose their CKD etiology and maximally treat it? The development of AKI most likely was multifactorial and at best only associated with HTS-not necessarily provoked by HTSand may have occurred with or without HTS use.
Most AKI was transient in this paper, and hypernatremia (sodium >155 mmol/L) and hyperosmolality were more common in the AKI group. They state that this sodium level is an independent risk for AKI, but in our view, there is insufficient information here to make any clinical decisions upon which a sodium number is unsafe to supersede. A retrospective study comparing HTS to normal saline infusions in patients at risk of developing intracranial hypertension showed that HTS given for 24 hours or longer resulted in an increase in serum sodium, creatinine, and blood urea nitrogen but no increase in the relative risk of developing AKI. 11 Some clinicians, looking at serum osmolalities, may conflate HTS (a volume expander) and mannitol (a volume depleter); 1 study comparing these medications found: ''cumulative urine output was statistically higher in patients who received mannitol,'' and ''cumulative fluid balance was statistically more negative than HTS-treated patients.'' 12 It is a volume depletion, not necessarily serum osmolality, that causes AKI.
More studies are needed on the use of HTS in cerebral edema-its administration (infusion vs boluses), its indication (which stroke subtypes and when), and its outcomes (mortality) in order to confirm its likely benefit and to boost its recommendation. In the grand inventory of all medications utilized in the NICU, HTS is probably among the more benign; early and continuous infusion of HTS in patients with severe spontaneous intracerebral hemorrhage was ''feasible and safe'' 6 for critically ill patients with severe stroke or traumatic brain injury without major side effects, 13 even up to sodium values of 160 mmol/L and osmolality values up to 320 mOsm/kg. 14 Should stroke patients avoid HTS for fear of AKI? Not if the purpose of using HTS is to mitigate cerebral edema and prevent further permanent neurologic injury or even death. Should a patient presenting with 1 or even all 5 presumed ''risk factors for AKI'' be deprived HTS? Not if we prioritize preventing irreversible brain damage over reversible kidney injury. Unsurprisingly, stroke patients' mortality is not from end-stage renal disease but rather from intracranial causes. 15, 16 Our message is simple: treat cerebral edema first and clean up the tinkertoys later. Otherwise, we are just adding more salt to the wounds.
